PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: IMARC Group

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Rising Diabetes Epidemic Offering Huge Opportunities for Drug Manufacturers in China Finds IMARC Group - With the Chinese population getting richer, fatter and less mobile; there has been a surge in the prevalence of diabetes in recent years - IMARCgroup.com
Rising Diabetes Epidemic Offering Huge Opportunities for Drug Manufacturers in China Finds IMARC Group

 

NewswireToday - /newswire/ - Noida, Uttar Pradesh, India, 2012/03/19 - With the Chinese population getting richer, fatter and less mobile; there has been a surge in the prevalence of diabetes in recent years - IMARCgroup.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

As the second largest economy of the world, China enjoys pink of health but its affluence is giving rise to another sickness - a rapid increase in a life-style disease called diabetes. With the Chinese Population getting richer, fatter and less mobile, there has been a surge in the prevalence of diabetes. A new study from IMARC Group, one of the world’s leading research and advisory firms, finds that with around 94 Million patients, China currently represents the diabetes capital of the world. The study that has done a comprehensive analysis on the past, present and future diabetes epidemiology and market trends in China, finds that by 2030 more than 139 million people will suffer from diabetes in the country. Findings from the report suggest that a rapidly ageing population, urbanization, nutritional changes, decreasing levels of physical activity and increasing obesity levels can be regarded as the main factors driving the prevalence of diabetes in China.

The increasing prevalence of diabetes is ringing alarm bells for the government and healthcare agencies. For Drug manufacturers, however, this represents a huge opportunity. The report expects the combined sales of oral antidiabetics and insulin to grow at a CAGR of 28%, exceeding revenues worth US$ 2.8 Billion by 2015.

IMARC’s new report “China Diabetes Market Outlook (2010-2015)” gives a deep insight into the Chinese diabetes market. The research study serves as an analytical as well as statistical tool to understand the epidemiology, trends, market structure and segmentation, competitive landscape, drivers, restraints and the outlook of the diabetes market in China. The report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are looking to foray into the Chinese diabetes market in some form or the other.

Forecasts: The report provides forecasts on:

• Number of diabetes patients
• Diagnosis and treatment rates in China
• Diabetes market
• Non-Insulin Anti-diabetics market
- Alpha-Glycosidase Inhibitors
- Glinides
- Glitazones
- Sulphonylureas
- DPP-IV Inhibitors
- Biguanides
- GLP-1 Agonists
- All other Non-Insulin Anti-diabetic classes
• Insulin market

Competitive Landscape: This section covers
• 2005-2009 sales and market shares of top players in the diabetes market
• 2005-2009 sales and market shares of top players in the Non-Insulin Anti-diabetics market
• 2005-2009 sales and market shares of top players in various Non-Insulin Drug Classes
• 2005-2009 sales of top drugs comprising the portfolio of key players in various Non-Insulin Drug Classes
• 2005-2009 sales and market shares of top players in the Insulin market
• 2005-2009 sales of top drugs comprising the portfolio of Key players in the Insulin market.

Key Questions Answered in this report
• What is the total size of the diabetes population in China and what are its characteristics?
• What are the diagnosis and drug treatment rates for diabetes in China?
• What are the key factors driving the growth of diabetes medication in China?
• What is the Size and Breakup of the total diabetes market in China?
• What is the Size and Breakup of the total Non-Insulin Anti-diabetics market in China?
• What is the Size and Breakup of the total Insulin market in China?
• Who are the key players in the Chinese diabetes market and how have they performed?
• What is the outlook of the Chinese diabetes market in the next five years?
• Which new products are expected to be launched in the next five years?
• Which therapy classes will show the highest growth in the next five years?
• What are the road blocks in the Chinese diabetes market?

To obtain the complete report, please contact:

IMARC Group Asia
E: apac[.]imarcgroup.com - P: +91-120-425-6531

IMARC Group North America
E: america[.]imarcgroup.com - P: +1-631-791-1145

To know more please visit imarcgroup.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: IMARC Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Rising Diabetes Epidemic Offering Huge Opportunities for Drug Manufacturers in China Finds IMARC Group

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Krishna Sharma - IMARCgroup.com 
+91 12 04155099 press[.]imarcgroup.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any IMARC Group securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From IMARC Group / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution
PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions
First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Al Rowaad Advocates & Legal Consultants

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)